Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.82 |
| ▸ | FNTA | P49354 | 6/20 | 0.53 |
| ▸ | FNTB | P49356 | 6/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25184624 | 0.97 | NR3C1 (0.85) | NR3C1FNTAFNTBHIF1ASMN1; SMN2 | |
| SCHEMBL10394058 | 0.93 | NR3C1 (0.79) | NR3C1FNTAFNTBHIF1ASMN1; SMN2 | |
| SCHEMBL14804028 | 0.93 | NR3C1 (0.79) | NR3C1FNTAFNTBHIF1ASMN1; SMN2 | |
| SCHEMBL15753111 | 0.92 | NR3C1 (0.81) | NR3C1FNTAFNTBHIF1ASMN1; SMN2 | |
| SCHEMBL3437593 | 0.91 | NR3C1 (0.83) | NR3C1FNTAFNTBHIF1ASMN1; SMN2 | |
| Anecortave Acetate SCHEMBL2118233 | 0.90 | NR3C1 (1.00) | NR3C1FNTAFNTBHIF1ASMN1; SMN2 | |
| Anecortave Acetate SCHEMBL8470303 | 0.90 | NR3C1 (1.00) | NR3C1FNTAFNTBHIF1ASMN1; SMN2 | |
| Anecortave Acetate SCHEMBL14612532 | 0.90 | NR3C1 (1.00) | NR3C1FNTAFNTBHIF1ASMN1; SMN2 | |
| Anecortave Acetate SCHEMBL94110 | 0.90 | NR3C1 (1.00) | NR3C1FNTAFNTBHIF1ASMN1; SMN2 | |
| SCHEMBL25171465 | 0.90 | NR3C1 (0.82) | NR3C1FNTAFNTBHIF1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-10000525-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180015104-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2018-01-18 | — | — | US | disclosed |
| US-9649320-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170027959-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC | 2017-02-02 | — | — | US | disclosed |
| US-20160375037-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2016-12-29 | — | — | US | disclosed |
| US-9434758-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160060289-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA B FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9198921-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150011519-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2015-01-08 | — | — | US | disclosed |
| US-20140142078-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | ReveraGen Biopharma (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130196962-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE | VALIDUS BIOPHARMA, INC (US) | 2013-08-01 | — | — | US | disclosed |
| US-8334279-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | VALIDUS GENETICS (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885FNTA 2077/4885FNTB 1122/4885 |
| US-20150011519-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885FNTA 323/4885FNTB 341/4885 |
| US-20180015104-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885FNTA 2077/4885FNTB 1122/4885 |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | NFKBIA, NFKB2, IKBKG | NR3C1 10/4885FNTA 532/4885FNTB 293/4885 |
| US-20160375037-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885FNTA 323/4885FNTB 341/4885 |
| US-20170027959-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885FNTA 2077/4885FNTB 1122/4885 |
| US-10000525-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | NFKBIA, NFKB2, NFKB1 | NR3C1 8/4885FNTA 2084/4885FNTB 1215/4885 |
| US-20140142078-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885FNTA 2077/4885FNTB 1122/4885 |
| US-20160060289-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA B FOR TREATMENT OF DISEASE | NFKBIA, IKBKG, NFKB2 | NR3C1 8/4885FNTA 1878/4885FNTB 1128/4885 |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885FNTA 2077/4885FNTB 1122/4885 |
| US-20130196962-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885FNTA 2077/4885FNTB 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.